Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital

Introduction Cancer patients are more vulnerable to coronavirus disease 2019 (COVID-19) owing to their compromised immune status. However, data regarding COVID-19 vaccine safety and immune response in cancer patients are scarce. Method This prospective, age- and sex-matched, single-center cohort stu...

Full description

Bibliographic Details
Main Authors: Piyarat Limpawittayakul, Prakongboon Sungkasubun, Worawit Chaiwiriyawong, Archara Supavavej, Bowon Weerasubpong, Jomtana Siripaibun, Chumut Phanthunane, Wisut Lamlertthon, Teerapat Ungtrakul, Kriangkrai Tawinprai, Walaipan Tantiyavarong, Chayanee Samdaengpan
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
chadox1 ncov-19
azd1222
vaccine
solid cancer
seropositivity
titer
Online Access:http://dx.doi.org/10.1080/21645515.2022.2104058

Internet

http://dx.doi.org/10.1080/21645515.2022.2104058

Similar Items